Immutep’s ADS count is expected to decline from approximately 32.8 million to approximately 1.64 million when its revised ADS ratio takes effect on September 28, 2026. The change is intended to help the Nasdaq-listed ADSs satisfy the $1.00 minimum bid requirement before the company’s October 26, 2026 compliance deadline.

Key Highlights

  • Immutep’s 1,473,721,306 ordinary shares will remain unchanged after the ADS adjustment.
  • BNY will aggregate fractional ADS entitlements and distribute cash without deducting a fee.
  • Holders of physical ADR certificates should contact BNY or their broker about the conversion.

Immutep Limited (NASDAQ: IMMP) is a biotechnology company. Its ADS count is expected to move from approximately 32.8 million to approximately 1.64 million when a revised ADS ratio takes effect on September 28, 2026. The change is aimed at helping the Nasdaq-listed ADSs meet the $1.00 minimum bid requirement before the October 26, 2026 compliance deadline.

Revised ADS Basis Begins September 28

Trading on the Nasdaq Global Market will begin under the revised basis on September 28, 2026. Immutep’s ordinary-share count will remain 1,473,721,306, and the adjustment will not change the number of ordinary shares issued. The ticker IMMP stays unchanged, while the ADS security receives a new CUSIP and ISIN; the ordinary-share ISIN remains unchanged. The change does not alter Immutep’s capital structure, cash position or clinical development programmes.

Nasdaq Compliance Test Sets the Timeline

Nasdaq notified Immutep that its ADS closing bid price had remained below $1.00, creating a continued-listing compliance issue under Nasdaq Listing Rule 5450(a)(1). The company must bring the closing bid price to at least $1.00 for the required consecutive-business-day test before October 26, 2026. September 29, 2026 will be the first trading day counted toward that requirement. Immutep said the revised ratio was chosen to create a Margin above $1.00 rather than mirror the current ADS trading price.